X0609 4 2026-06-11 0 0001919246 Pelthos Therapeutics Inc. PTHS 0001392029 Davis Todd C false C/O PELTHOS THERAPEUTICS INC. 4020 STIRRUP CREEK DRIVE, SUITE 110 DURHAM NC 27703 1 0 0 0 0 Common Stock 2026-06-11 4 P 0 35445 27.8046 A 75331 D Common Stock 2026-06-11 4 P 0 503 28.7261 A 75834 D Common Stock 1500000 I By Ligand Pharmaceuticals Incorporated This transaction was executed in multiple trades at prices ranging from $27.63 to $28.49. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $28.72 to $28.94. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock purchased. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Todd Davis is the Chief Executive Officer and a member of the board of directors of Ligand Pharmaceuticals Inc. ("Ligand"). By virtue of this relationship, Mr. Davis may be deemed to beneficially own the shares of Common Stock held of record by Ligand. Mr. Davis disclaims any such beneficial ownership except to the extent of his pecuniary interest therein. /s/ John M. Gay, by power of attorney 2026-06-15